Mary M Chen

US Patent:

6860893, Mar 1, 2005

Filed:

Oct 9, 2001

Appl. No.:

09/974068

Inventors:

Michael P. Wallace - Pleasanton CA, US
Marc-Alan Levine - San Francisco CA, US
Delilah Yin Hui - Union City CA, US
Mary M. Chen - San Leandro CA, US
Liem Ho - Mountain View CA, US

Assignee:

Boston Scientific SciMed, Inc. - Maple Grove MN

International Classification:

A61M029/00

US Classification:

606200

Abstract:

This is an implantable vaso-occlusive device. The device has a complex, three-dimensional structure in a relaxed configuration that may be used in the approximate shape of an anatomical cavity. It may be deployed in the approximate shape of a sphere, an ovoid, a clover, a box-like structure or other distorted spherical shape. The loops forming the relaxed configuration may pass through the interior of the structure. The device is a self-forming shape made from a pre-formed linear vaso-occlusion member. Fibers may be introduced onto the device and affixed to the pre-formed linear member. The constituent member may be also be covered with a fibrous braid. The device is typically introduced through a catheter. The device is passed axially through the catheter sheath and assumes its form upon exiting the catheter without further action. The invention also includes methods of winding the anatomically shaped vaso-occlusive device into appropriately shaped forms and annealing them to form various devices.

US Patent:

7947280, May 24, 2011

Filed:

Nov 14, 2007

Appl. No.:

11/985460

Inventors:

Euan A. Ashley - Palo Alto CA, US
Mary M. Chen - Fremont CA, US
Thomas Quertermous - Stanford CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 39/00
C07K 4/00
C07K 4/12

US Classification:

4241851, 530327

Abstract:

The invention provides a method of treating or preventing heart failure or a disease or condition associated with heart failure comprising administering an effective dose of an apelin peptide or APJ receptor ligand to the subject. According to certain embodiments of the invention the apelin peptide is administered chronically. In certain embodiments of the invention the apelin peptide is administered in an amount effective to improve at least one hemodynamic parameter or prognostic variable for heart failure. Clinical conditions associated with heart failure include, but are not limited to, atherosclerosis, restenosis, ischemic cardiovascular diseases, idiopathic or viral cardiomyopathy, and the like.

US Patent:

20040048368, Mar 11, 2004

Filed:

Aug 8, 2003

Appl. No.:

10/637918

Inventors:

Mary Chen - Burlingame CA, US
Lawrence Forman - Sunnyvale CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N005/02

US Classification:

435/325000, 435/383000

Abstract:

A method-of producing a polypeptide in fed batch cell culture is provided which involves an initial cell growth phase and a distinct production phase. In the initial growth stage, animal cells having nucleic acid encoding the polypeptide are cultured at a starting osmolality of about 280-330 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0.01 and 1 g/L. This is followed by a production phase, where the cultured animal cells of the growth phase are inoculated at a cell seed density of at least 1.0×10cells/mL and the cells are cultured at a starting osmolarity of about 400-600 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0.01 and 1 g/L. Preferably, the glutamine concentration in the cell culture medium is simultaneously controlled in order to curtail production of lactic acid and ammonia which result from unnecessarily high glutamine concentrations. During the growth phase, production of potentially detrimental metabolic waste products, such as lactic acid, is controlled thereby curtailing the increase of osmolality due to accumulation and neutralization of waste products. Thus, the cell growth can be improved. In the production phase, the cell culture conditions are modified in order to arrest or reduce cell growth and thereby direct nutrient utilization toward production, as opposed to cell growth. Overall, it is intended that the method results in an improvement in specific productivity, reduction in production run times and/or an increase in final product concentration.

US Patent:

20050152836, Jul 14, 2005

Filed:

May 21, 2004

Appl. No.:

10/850941

Inventors:

Euan Ashley - Palo Alto CA, US
Mary Chen - Fremont CA, US
Thomas Quertermous - Stanford CA, US
David Xing-Fei Deng - Mountain View CA, US
Anya Tsalenko - Chicago IL, US
Amir Ben-dor - Bellevue WA, US
Laurakay Bruhn - Mountain View CA, US
Zohar Yakhini - Ramat HaSharon, IL

International Classification:

A61K051/00
C12Q001/68
G01N033/53
G01N033/567
C07K016/46

US Classification:

424001490, 435006000, 435007200, 530391100

Abstract:

The invention identifies genes whose expression is upregulated or downregulated following mechanical offloading in subjects with heart failure. The invention provides compositions comprising a targeting agent conjugated to a functional moiety, wherein the targeting agent selectively binds to a polypeptide encoded by one of these genes. The functional moiety can be an imaging agent, therapeutic agent, etc. The invention further provides methods for providing diagnostic or prognostic information related to heart failure involving detecting expression or activity of an expression product of one or more of the identified genes. The invention further provides diagnostic and therapeutic methods comprising detecting or administering an apelin peptide to a subject.

US Patent:

20050272124, Dec 8, 2005

Filed:

Jun 29, 2005

Appl. No.:

11/172090

Inventors:

Mary Chen - Burlingame CA, US
Lawrence Forman - Sunnyvale CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12P021/06
C12N005/06

US Classification:

435069100, 435358000, 435320100

Abstract:

A method of producing a polypeptide in fed batch cell culture is provided which involves an initial cell growth phase and a distinct production phase. In the initial growth stage, animal cells having nucleic acid encoding the polypeptide are cultured at a starting osmolality of about 280-330 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0.01 and 1 g/L. This is followed by a production phase, where the cultured animal cells of the growth phase are inoculated at a cell seed density of at least 1.0×10cells/mL and the cells are cultured at a starting osmolarity of about 400-600 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0.01 and 1 g/L. Preferably, the glutamine concentration in the cell culture medium is simultaneously controlled in order to curtail production of lactic acid and ammonia which result from unnecessarily high glutamine concentrations. During the growth phase, production of potentially detrimental metabolic waste products, such as lactic acid, is controlled thereby curtailing the increase of osmolality due to accumulation and neutralization of waste products. Thus, the cell growth can be improved. In the production phase, the cell culture conditions are modified in order to arrest or reduce cell growth and thereby direct nutrient utilization toward production, as opposed to cell growth. Overall, it is intended that the method results in an improvement in specific productivity, reduction in production run times and/or an increase in final product concentration.

US Patent:

61804010, Jan 30, 2001

Filed:

May 4, 1998

Appl. No.:

9/073198

Inventors:

Mary Chen - Burlingame CA
Lawrence W. Forman - Sunnyvale CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 500
C12N 506

US Classification:

435358

Abstract:

A method of producing a polypeptide in fed batch cell culture is provided which involves an initial cell growth phase and a distinct production phase. In the initial growth stage, animal cells having nucleic acid encoding the polypeptide are cultured at a starting osmolality of about 280-330 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0. 01 and 1 g/L. This is followed by a production phase, where the cultured animal cells of the growth phase are inoculated at a cell seed density of at least 1. times. 10. sup. 6 cells/mL and the cells are cultured at a starting osmolarity of about 400-600 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0. 01 and 1 g/L. Preferably, the glutamine concentration in the cell culture medium is simultaneously controlled in order to curtail production of lactic acid and ammonia which result from unnecessarily high glutamine concentrations.

US Patent:

58561790, Jan 5, 1999

Filed:

Mar 10, 1994

Appl. No.:

8/208888

Inventors:

Mary Chen - Burlingame CA
Lawrence W. Forman - Sunnyvale CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 500
C12P 2106
C12P 2102
C12P 2104

US Classification:

435325

Abstract:

A method of producing a polypeptide in fed batch cell culture is provided which involves an initial cell growth phase and a distinct production phase. In the initial growth stage, animal cells having nucleic acid encoding the polypeptide are cultured at a starting osmolality of about 280-330 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0. 01 and 1 g/L. This is followed by a production phase, where the cultured animal cells of the growth phase are inoculated at a cell seed density of at least 1. times. 10. sup. 6 cells/mL and the cells are cultured at a starting osmolarity of about 400-600 mOsm in the presence of a concentration of glucose controlled throughout the culturing to be within a range between about 0. 01 and 1 g/L. Preferably, the glutamine concentration in the cell culture medium is simultaneously controlled in order to curtail production of lactic acid and ammonia which result from unnecessarily high glutamine concentrations.

US Patent:

6322576, Nov 27, 2001

Filed:

Feb 4, 1998

Appl. No.:

9/018278

Inventors:

Michael P. Wallace - Pleasanton CA
Marc-Alan Levine - San Francisco CA
Delilah Yin Hui - Union City CA
Mary M. Chen - San Leandro CA
Liem Ho - Mountain View CA

Assignee:

Target Therapeutics, Inc. - Fremont CA

International Classification:

A61B 1700

US Classification:

606191

Abstract:

This is an implantable vaso-occlusive device. The device has a complex, three-dimensional structure in a relaxed configuration that may be used in the approximate shape of an anatomical cavity. It may be deployed in the approximate shape of a sphere, an ovoid, a clover, a box-like structure or other distorted spherical shape. The loops forming the relaxed configuration may pass through the interior of the structure. The device is a self-forming shape made from a pre-formed linear vaso-occlusion member. Fibers may be introduced onto the device and affixed to the pre-formed linear member. The constituent member may be also be covered with a fibrous braid. The device is typically introduced through a catheter. The device is passed axially through the catheter sheath and assumes its form upon exiting the catheter without further action. The invention also includes methods of winding the anatomically shaped vaso-occlusive device into appropriately shaped forms and annealing them to form various devices.